Interstitial Lung Disease in Polymyositis and Dermatomyositis

Area of Science:

• Rheumatology
• Immunology
• Pulmonology

Background:

• Idiopathic inflammatory myopathies (IIMs), encompassing polymyositis (PM) and dermatomyositis (DM), are autoimmune diseases characterized by muscle inflammation and potential systemic effects.
• Interstitial lung disease (ILD) is a frequent and serious complication of IIMs, significantly contributing to patient mortality.
• The presence of myositis-specific and myositis-associated antibodies (MSA/MAAs) in patients with PM/DM correlates with specific clinical presentations.

Purpose of the Study:

• To review the association between specific myositis-specific antibodies (MSAs) and the occurrence of interstitial lung disease (ILD) in patients with idiopathic inflammatory myopathies (IIMs).
• To highlight the clinical significance of MSAs in predicting ILD and guiding treatment strategies for IIMs.

Main Methods:

• Literature review focusing on idiopathic inflammatory myopathies, myositis-specific antibodies, and interstitial lung disease.
• Analysis of studies correlating specific antibody profiles (e.g., anti-aminoacyl-tRNA, anti-melanoma differentiation factor 5) with ILD prevalence in IIM cohorts.

Main Results:

• Certain MSAs, including anti-aminoacyl-tRNA antibodies and anti-melanoma differentiation factor 5 (MDA5) antibodies, are strongly associated with a higher incidence of ILD in IIM patients.
• These antibodies contribute to distinct clinical phenotypes, with ILD being a prominent feature.

Conclusions:

• Identifying specific MSAs can aid in predicting the risk of developing ILD in patients with IIMs.
• While corticosteroids are foundational, combination immunosuppressive therapy is often essential for managing IIMs with significant ILD.
• Further research into targeted therapies based on antibody profiles may improve outcomes for IIM patients with ILD.